Try our Advanced Search for more refined results
Life Sciences
-
November 14, 2025
ITC To Scrutinize Redesigned Apple Watch In Masimo IP Fight
The U.S. International Trade Commission said Friday that it would review whether redesigned Apple Watches violate a previous order that briefly blocked imports of the devices deemed to infringe a pair of patents owned by Masimo, which urged the ITC to scrutinize the modified products.
-
November 14, 2025
Ethiopian Importer Asks Court To Enforce $5M Arbitration Win
An Ethiopian import company has asked a California federal court to enforce a $5.3 million arbitral award against a medical supply company following a dispute over a botched contract.
-
November 14, 2025
Drug Buyers Defend Class Cert. In 3rd Circ. Generics Case
Direct purchasers and end-payers in the sprawling multidistrict litigation over alleged price-fixing of generic drugs are fighting requests from Actavis and Mylan to undo class certification in the cases, arguing to the Third Circuit that the litigation is a classic example of a class action matter.
-
November 14, 2025
Tricida Trustee Jackson Square Sues Over $740M Loss
The liquidating trustee for bankrupt drug developer Tricida has filed a complaint in U.S. Bankruptcy Court for the District of Delaware accusing seven former executives and directors, along with an investment firm, of systematically stripping more than $740 million in corporate assets through insider trading, self-approved bonuses and a deliberate failure to protect valuable tax attributes before its 2023 collapse.
-
November 14, 2025
DOJ Official Among Trump Picks For District Courts
President Donald Trump announced judicial nominees for federal courts in Tennessee, Indiana and Missouri on Friday, including a current U.S. Department of Justice official.
-
November 14, 2025
DC Circ. Wary Of DEA Delays In Religious Ayahuasca Case
A D.C. Circuit panel on Friday appeared skeptical that the Drug Enforcement Administration was justified in its delays processing an Iowa church's application for a religious exemption to the Controlled Substances Act to use a psychedelic in its rites.
-
November 14, 2025
Taxation With Representation: Wachtell, Paul Hastings, Sidley
In this week's Taxation With Representation, Pfizer Inc. completes its acquisition of obesity drug developer Metsera Inc., motion and controls technologies company Parker-Hannifin Corp. acquires Filtration Group Corp., and fund administrator JTC PLC backs a cash offer in the billions from British private equity shop Permira.
-
November 14, 2025
Photographer Sues Gilead For Continued Use Of Ad Images
A photographer sued Gilead Sciences Inc., claiming the pharmaceutical giant had used a set of images he'd taken for an advertisement series long after it knew its license for the photos expired.
-
November 14, 2025
Purdue's $7.4B Ch. 11 Plan To Be Confirmed
A New York bankruptcy judge agreed to confirm the $7.4 billion Chapter 11 plan of Purdue Pharma LP on Friday, saying he would issue a formal bench ruling next Tuesday explaining his decision.
-
November 14, 2025
Gibson Dunn, Cooley Guide Merck's $9.2B Cidara Buy
Gibson Dunn & Crutcher LLP-advised Merck on Friday said it will broaden its respiratory portfolio with a $9.2 billion deal to buy Cooley LLP-led Cidara Therapeutics, betting that an investigational antiviral could help the company tackle the global health burden of seasonal influenza.
-
November 13, 2025
J&J Bellwether Trial Over Talc Cancer Risks Kicks Off In LA
An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a Los Angeles jury Thursday during opening statements in a bellwether trial that decades-old internal documents prove J&J knew its talc products contained toxic levels of asbestos but hid that information.
-
November 13, 2025
Hemp Policy At Crossroads After Government Reopening Bill
Hemp industry advocates are pledging to use the one-year gap between enactment and implementation of the government funding agreement, which effectively recriminalized most hemp-derived THC products, to craft new regulatory legislation that stops short of a full ban.
-
November 13, 2025
NC Biz Court Bulletin: Rulings Spotlight Coverage Clashes
The North Carolina Business Court plowed into the fourth quarter with two big decisions in insurance disputes that involved $50 million in COVID-19-related losses at a chain of outlet malls, and an industrial accident at a Nucor Corp. iron plant in Louisiana.
-
November 13, 2025
Weight-Loss Drug MDL In Pa. Grows With 3 New Jersey Cases
Three New Jersey cases were grouped into multidistrict litigation accusing Eli Lilly & Co. and Novo Nordisk of downplaying alleged side effects of weight loss drugs like Ozempic and Trulicity, according to a transfer order filed in Pennsylvania federal court.
-
November 13, 2025
Mich. Schools Sue Over Privacy Waiver In Funding Bill
A group of school districts and leaders have sued the state of Michigan in state and federal courts, asking judges to bar the state from enforcing a portion of a recently passed school funding legislative package that would require schools to give up privacy privileges in mass casualty events to receive mental health or safety dollars.
-
November 13, 2025
Fenwick, WilmerHale Steer $285M Mersana Take-Private Deal
Pediatric cancer-focused biopharmaceutical company Day One Biopharmaceuticals, led by Fenwick & West LLP, announced plans Thursday to acquire clinical-stage biopharmaceutical company Mersana Therapeutics Inc., advised by WilmerHale, in a take-private deal worth up to $285 million.
-
November 13, 2025
3rd Circ. Says Quest Didn't Eavesdrop In Data Privacy Suit
The Third Circuit on Thursday upheld a win for Quest Diagnostics, which beat a class action alleging it inappropriately shared patient data with Meta Platforms through ad tracking software on its website, with the court reasoning that information was not unlawfully collected because it wasn't obtained through eavesdropping.
-
November 13, 2025
Wachtell-Led Pfizer Closes Metsera Deal Worth Up To $10B
Pfizer Inc. said Thursday that it has successfully completed its acquisition of Metsera Inc., securing the obesity drug developer after a tumultuous bidding war with Novo Nordisk and court fights that redirected the deal in Pfizer's favor.
-
November 13, 2025
FTC Fails To Block Doctors' Testimony In $945M Merger Case
A D.C. federal judge refused Thursday to bar a pair of outside doctors and consultants from vouching for Edwards Lifesciences Corp.'s planned JenaValve Technology Inc. acquisition, preferring to let the Federal Trade Commission contest their testimony in cross-examination and saying from the bench that he'll "make some popcorn."
-
November 13, 2025
Claims Firms Accused Of Misleading Plaintiffs In Pharma MDL
A Pennsylvania federal judge has been asked to slow down aggressive marketing campaigns from claims recovery firms that are accused of using false and misleading advertising to attract plaintiffs in a multidistrict litigation action against pharmaceutical companies.
-
November 12, 2025
Biotech Co., Founders Can't Duck $14.3M SEC Payment
A Colorado federal judge has rejected a biotech startup and two of its founders' bid to reconsider a February order requiring them to pay the U.S. Securities and Exchange Commission more than $14.3 million for overstating their own investments in the company.
-
November 12, 2025
Valsartan Cancer Expert Blocked, Ending First Injury Trial
What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.
-
November 12, 2025
Sandoz Tells 3rd Circ. To Restore Full $137M Win Over UTC
Sandoz Inc. and its marketing firm RareGen LLC urged a Third Circuit panel on Wednesday to reinstate the full $137.2 million awarded in breach of contract damages against United Therapeutics Corp., claiming a lower court's decision to halve the damages provided a windfall to their adversary.
-
November 12, 2025
NJ Justices Keep Ozempic Injury Mass Torts Separate
The New Jersey Supreme Court has decided not to combine two Bergen County Superior Court mass tort cases over weight loss drugs including Ozempic, Wegovy and Mounjaro, keeping them separate based on the type of injury alleged.
-
November 12, 2025
Purdue Kicks Off Ch. 11 Confirmation With Plan Overview
Bankrupt OxyContin maker Purdue Pharma began its Chapter 11 confirmation trial Wednesday with an overview of its latest plan and the myriad settlements that underpin the proposal, including a $6.5 billion commitment from the company's owners.
Expert Analysis
-
Rebuttal
BigLaw Settlements Should Not Spur Ethics Deregulation
A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project.
-
How Big Pharma Has Responded To FTC Delisting Demands
Looking at some statistics concerning how pharmaceutical companies have responded to the Federal Trade Commission's recent challenges to Orange Book listings raises several possible hypotheses about the FTC's strategy and effectiveness, say Ratib Ali and Celia Lu at Competition Dynamics.
-
5 Ways Lawyers Can Earn Back The Public's Trust
Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law.
-
USPTO's AI Tool Redefines Design Patent Landscape
The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.
-
Class Actions At The Circuit Courts: August Lessons
In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses key takeaways from federal appellate decisions involving topics including antitrust, immigration, consumer fraud, birthright citizenship under the Fourteenth Amendment, and product defects.
-
Series
Hiking Makes Me A Better Lawyer
On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag.
-
What US-India Trade Deal Will Mean For Indian Pharma
Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners.
-
Opinion
Time For Full Disclosure Of Third-Party Funding In MDLs
It is appropriate that the Federal Advisory Committee on Civil Rules is considering a rule to require disclosure of third-party litigation funding in civil litigation — something that is particularly needed in multidistrict litigation, which now comprises more than half of all civil cases in the federal courts, says Eric Hudson at Butler Snow.
-
Series
Law School's Missed Lessons: Negotiation Skills
I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron.
-
Conflicting Developments In Homelessness Legal Landscape
Looking at an executive order and Third Circuit opinion from last month highlights the ongoing tension in homelessness-related legal issues facing state and local governments, property owners, and individuals experiencing homelessness, says Josh Collins, an attorney for the City of South Salt Lake.
-
AG Watch: Texas Embraces The MAHA Movement
Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.
-
Opinion
Bar Exam Reform Must Expand Beyond A Single Updated Test
Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.
-
The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult
A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.
-
Location Data And Online Tracking Trends To Watch
Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter.
-
A Simple Way Courts Can Help Attys Avoid AI Hallucinations
As attorneys increasingly rely on generative artificial intelligence for legal research, courts should consider expanding online quality control programs to flag potential hallucinations — permitting counsel to correct mistakes and sparing judges the burden of imposing sanctions, say attorneys at Lankler Siffert & Wohl and Connors.